MCRB(MCRB)
MCRB
ANALYST COVERAGE16 analysts
HOLD
▼ -84.5%downside to target
Key MetricsTTM
Market Cap$77.96M
Revenue TTM$1.15M
Net Income TTM-$46.90M
Free Cash Flow-$42.37M
Gross Margin-20.9%
Operating Margin-7641.0%
Net Margin-4088.8%
Return on Equity-127.3%
Return on Assets-39.9%
Debt / Equity3.04
Current Ratio1.65
EPS TTM$-4.89
PRICE
Prev Close
7.66
Open
7.51
Day Range7.51 – 8.09
7.51
8.09
52W Range6.56 – 29.98
6.56
29.98
6% of range
VOLUME & SIZE
Avg Volume
48.5K
FUNDAMENTALS
P/E Ratio
-1.6x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.48
Market-like
TECHNICAL
RSI (14)
40
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 96 days
Aug 26
MCRB News
About
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Eric Shaff
Website
Dennis WallingSenior Vice President of Clinical Development & Head of Clinical Research
Matthew R. HennPresident & Chief Scientific Officer
Teresa L. YoungExecutive Vice President and Chief Commercial & Strategy Officer
Marella ThorellExecutive VP, CFO & Treasurer
Kelly BradyExecutive VP & COO
Chris McChalicherExecutive Vice President & Chief Technology Officer
Richard N. KenderInterim CEO & Executive Chair
Thomas J. DesRosierExecutive VP, Chief Legal Officer & Secretary
Ann KurowskiSenior Vice President of Regulatory Affairs